Download PDF
Thromb Haemost 2001; 85(05): 941-942
DOI: 10.1055/s-0037-1615776
Letters to the Editor
Schattauer GmbH

Tamoxifen Increases von Willebrand Factor in Women who Underwent Breast Cancer Surgery

A. D. Blann
1   University Department of Surgery, University Hospital of South Manchester, Manchester
,
A. D. Baildam
1   University Department of Surgery, University Hospital of South Manchester, Manchester
,
A. Howell
1   University Department of Surgery, University Hospital of South Manchester, Manchester
,
J. P. Miller
1   University Department of Surgery, University Hospital of South Manchester, Manchester
› Author Affiliations
Further Information

Publication History

Received 13 November 2001

Accepted after resubmission 12 December 2000

Publication Date:
11 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Early Breast Cancer Trialists’ Collaborative Group.. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. New Engl J Med 1988; 319: 1681-92.
    CrossrefPubMedGoogle Scholar
  • 2 Pritchard KI, Paterson AHG, Paul NA, Zee B, Fine S, Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomised trial of adjuvant therapy for women with breast cancer. J Clin Oncol 1996; 14: 2731-7.
    CrossrefPubMedGoogle Scholar
  • 3 Blann AD, Lip GYH. The endothelium in cardiovascular disease: Functions, assessment and implications. Blood Coag Fibrinolys 1998; 9: 297-306.
    PubMedGoogle Scholar
  • 4 Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. New Engl J Med 1995; 332: 635-41.
    CrossrefPubMedGoogle Scholar
  • 5 Mannucci PM, Bettega D, Chantarangkul V, Tripoodi A, Sacchini V, Veronesi U. Effect of tamoxifen on measurement of hemostasis in healthy women. Arch Intern Med 1996; 156: 1806-10.
    CrossrefPubMedGoogle Scholar
  • 6 Ounnoughene N, Molho P, Stieltjes N, Sultan Y. Effect of tamoxifen on von Willebrand factor levels. Arch Intern Med 1997; 157: 1613.
    CrossrefPubMedGoogle Scholar
  • 7 Gralnick HR. von Willebrand factor, integrins, and platelets: Their role in cancer. J Lab Clin Med 1992; 119: 444-7.
    PubMedGoogle Scholar
  • 8 Uchiyama T, Matsumoto M, Kobayashi N. Studies on the pathogenesis of coagulopathy in patients with arterial thromboembolism and malignancy. Thromb Res 1990; 59: 955-65.
    CrossrefPubMedGoogle Scholar
  • 9 Licciardello JTW, Moake JL, Rudy CK, Karp DD, Hong WK. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 1985; 42: 296-300.
    CrossrefPubMedGoogle Scholar
  • 10 Nicolson GL, Cistead SW. Effects of chemotherapeutic drugs on platelet and metastatic tumour endothelial cell interactions as a model for assessing vascular endothelial integrity. Cancer Res 1985; 45: 331-6.
    PubMedGoogle Scholar